In addition, we observed a numerically higher proportion of HER2-low cases among recurrent breast cancer samples than primary tumors, similarly to a previous retrospective study in which HER2-low cases enriched the metastatic cohort as compared to the primary breast cancer population19. The gene discussed is ERBB2; the disease is breast cancer.